

A novel role for vitamin K1 in a tyrosine phosphorylation cascade during chick embryogenesis.

S P Saxena, T Fan, M Li, E D Israels, L G Israels

J Clin Invest. 1997;**99**(4):602-607. <https://doi.org/10.1172/JCI119202>.

Research Article

The development of the embryo is dependent upon a highly coordinated repertoire of cell division, differentiation, and migration. Protein-tyrosine phosphorylation plays a pivotal role in the regulation of these processes. Vitamin K-dependent gamma-carboxylated proteins have been identified as ligands for a unique family (Tyr 3 and 7) of receptor tyrosine kinases (RTKs) with transforming ability. The involvement of vitamin K metabolism and function in two well characterized birth defects, warfarin embryopathy and vitamin K epoxide reductase deficiency, suggests that developmental signals from K-dependent pathways may be required for normal embryogenesis. Using a chick embryogenesis model, we now demonstrate the existence of a vitamin K1-dependent protein-tyrosine phosphorylation cascade involving c-Eyk, a member of the Tyro 12 family, and key intracellular proteins, including focal adhesion kinase (pp125FAK), paxillin, and pp60src. This cascade is sensitive to alteration in levels or metabolism of vitamin K1. These findings provide a major clue as to why, in the mammalian (and human) fetus, the K-dependent proteins are maintained in an undercarboxylated state, even to the point of placing the newborn at hemorrhagic risk. The precise regulation of vitamin K1-dependent regulatory pathways would appear to be critical for orderly embryogenesis.

Find the latest version:

<https://jci.me/119202/pdf>



A Novel Role for Vitamin K₁ in a Tyrosine Phosphorylation Cascade during Chick Embryogenesis

Satya P. Saxena,**§ Tao Fan,*§ Mingyi Li,* Esther D. Israels,† and Lyonel G. Israels*||

*Manitoba Institute of Cell Biology and the †Department of Pediatrics, §Department of Physiology, and ||Department of Medicine, University of Manitoba, Winnipeg, Canada R3E 0V9

Abstract

The development of the embryo is dependent upon a highly coordinated repertoire of cell division, differentiation, and migration. Protein-tyrosine phosphorylation plays a pivotal role in the regulation of these processes. Vitamin K-dependent γ -carboxylated proteins have been identified as ligands for a unique family (Tyro 3 and 7) of receptor tyrosine kinases (RTKs) with transforming ability. The involvement of vitamin K metabolism and function in two well characterized birth defects, warfarin embryopathy and vitamin K epoxide reductase deficiency, suggests that developmental signals from K-dependent pathways may be required for normal embryogenesis. Using a chick embryogenesis model, we now demonstrate the existence of a vitamin K₁-dependent protein-tyrosine phosphorylation cascade involving c-Eyk, a member of the Tyro 12 family, and key intracellular proteins, including focal adhesion kinase (pp125^{FAK}), paxillin, and pp60^{src}. This cascade is sensitive to alteration in levels or metabolism of vitamin K₁. These findings provide a major clue as to why, in the mammalian (and human) fetus, the K-dependent proteins are maintained in an undercarboxylated state, even to the point of placing the newborn at hemorrhagic risk. The precise regulation of vitamin K₁-dependent regulatory pathways would appear to be critical for orderly embryogenesis. (*J. Clin. Invest.* 1997; 99: 602–607.) Key words: K-dependent proteins • receptor tyrosine kinases • warfarin • focal adhesion kinase • paxillin

Introduction

Vitamin K₁ (2 methyl-3-phytyl-1, 4 naphthoquinone) is an essential cofactor for the carboxylase involved in the posttranslational γ -carboxylation of a series of glutamic acid residues in juxtaposition to the NH₂ terminus of the vitamin K-dependent proteins (1–3). These γ -carboxyglutamic acid (Gla)¹ residues

facilitate the binding of vitamin K-dependent proteins to membrane phospholipids in the presence of calcium (4, 5). The vitamin K₁ level in the mammalian fetus is tightly regulated by a maternal/fetal placental gradient (6); the median vitamin K₁ concentration in human cord plasma is 16 pg/ml as compared with a maternal median plasma level of 470 pg/ml. This lower vitamin K₁ concentration in the fetus and newborn is reflected in reduced γ -carboxylation of coagulation factors II, VII, IX, and X, Proteins C and S, and bone protein matrix-Gla protein and osteocalcin (7). Although delayed osteocalcin production without rigid skeletal formation may be of benefit to the fetus, the low levels of the coagulation factors with the attendant hemorrhagic risk is difficult to explain.

The identification of several receptor and nonreceptor kinases in embryonic tissues (8, 9), accompanied by major temporal changes in the levels of protein-tyrosine phosphorylation (10) and tyrosine kinase activity (11) during embryonic development, suggests that such posttranslational modification of target proteins is key to the regulation of orderly embryogenesis. The extensive sequence similarity shared by tyrosine kinase domains has helped in homology-based cloning of a unique group of receptor tyrosine kinases (RTKs), Tyro 3 (alternatively called Sky, Rse, Brt, or Tif), Tyro 7 (alternatively called Axl, UFO, or Ark), and Tyro 12 (alternatively called c-Eyk or c-mer) (12). The extracellular domain of the Tyro 3, 7, and 12 family of RTKs consists of a combination of fibronectin type III and immunoglobulin motifs common to extracellular matrix proteins, neural cell adhesion molecules, and cell surface receptors with tyrosine kinase or phosphatase activities (13, 14). It is believed that these RTKs may be bifunctional, acting both as cell adhesion proteins and as components of signal transduction. Recently, Protein S, a vitamin K-dependent coagulation inhibitor (15), and its relative Gas6, a protein encoded by the growth arrest specific gene (16), have been identified, respectively, as classical ligands for the Tyro 3 and Tyro 7 family of RTKs (17–22). The role of this novel vitamin K-dependent receptor-ligand system in cellular processes is not clear but studies showing transforming activity of Axl in NIH 3T3 cells (23, 24), and the mitogenic potential of Protein S in smooth muscle cells (25) suggest a role in growth regulation.

The chick embryo has been used as a model system to study the signaling pathways operative during embryonic development. Since c-Eyk, a chicken counterpart of the Tyro 12 family of RTKs, exhibits a broad spatial and temporal expression during development (26), we sought to explore a possible vitamin K-dependent regulatory pathway(s) in a chick model of embryogenesis. We report the existence of a vitamin K₁-dependent protein-tyrosine phosphorylation cascade involving c-Eyk and key intracellular proteins, including focal adhesion kinase (pp125^{FAK}), paxillin, and pp60^{src}, which are all integral to chick embryogenesis.

Address correspondence to Dr. Lyonel G. Israels, Manitoba Institute of Cell Biology, 100 Olivia Street, Winnipeg, Manitoba, R3E 0V9, Canada. Phone: 204-787-2246; FAX: 204-787-2190; E-mail: saxen@cc.umanitoba.ca

Received for publication 18 July 1996 and accepted in revised form 27 November 1996.

1. Abbreviations used in this paper: anti-PY, anti-phosphotyrosine; Gla, γ -carboxyglutamic acid; pp125^{FAK}, focal adhesion kinase; RTKs, receptor tyrosine kinases.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/97/02/0602/06 \$2.00

Volume 99, Number 4, February 1997, 602–607

Methods

Animal model and drug administration. Fertile eggs from Cornish hens were incubated at 37°C and 85% humidity and rotated hourly. At days 10 or 16, a small hole was made in the shell directly over the air sac and varying amounts of vitamin K₁ (in 10 μ l acetone) alone or in combination with water soluble warfarin were injected onto the inner membrane with a Hamilton syringe; noninjected eggs and eggs receiving 10 μ l acetone alone served as controls and vehicle (acetone) controls, respectively. After 48 h incubation, the embryonic tissues removed on days 12 and 18 were rinsed vigorously in ice cold phosphate-buffered saline with 1mM sodium orthovanadate and used for protein extraction.

Protein extraction. Freshly harvested tissues were homogenized in lysis buffer containing 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 10 mM Tris-HCl (pH 7.6), 158 mM NaCl, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM PMSF, 10 μ g/ml leupeptin, and 1 μ g/ml aprotinin. After 30 min on ice, detergent insoluble material was removed by centrifugation at 14,000 rpm at 4°C for 15 min. Aliquots (5–10 μ l) of supernatant were used for protein determination by a bicinchoninic acid protein assay kit (Pierce Chemical Co., Rockford, IL).

Immunoprecipitation. 500 μ g of detergent soluble protein from the brain and liver of day 12 or day 18 embryos were pre-cleared by mixing with normal rabbit serum-coated protein A-Sepharose 4B (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) for 1 h in the cold. The clarified tissue extracts were added to protein A-Sepharose beads previously incubated for 90 min with anti-pp125^{FAK} (Upstate Biotechnology Inc., Lake Placid, NY), anti-pp60^{Src} (Upstate Biotechnology Inc.), anti-paxillin (Transduction Laboratories, Lexington, KY) or anti-Eyk antibodies (gift of Dr. H. Hanafusa, The Rockefeller University, New York). After 3–4 h incubation at 4°C with gentle rocking, the beads were washed three times with cold lysis buffer containing 50 μ M sodium orthovanadate, once with 0.5 M LiCl₂/0.1 M Tris-HCl (pH 7.4), and twice with 10 mM Tris-HCl (pH 7.4). The

precipitated proteins recovered from the beads were subjected to immunoblotting studies and in vitro kinase assays.

SDS-PAGE and immunoblotting. 50 μ g protein samples of tissue extracts or immunoprecipitates were solubilized in SDS-sample buffer (62.5mM Tris, 10% glycerol, 2.3% SDS, 100 mM dithiothreitol, 0.1% bromophenol blue, pH 6.8), boiled for 5 min, and electrophoresed on 7.5% SDS-polyacrylamide gel electrophoresis (27). The proteins were then electrophoretically transferred onto nitrocellulose, filters blocked overnight in the cold with Tris-buffered saline containing 3% bovine serum albumin (Sigma Chemical Co., St. Louis, MO). Blots were incubated for at least 4 h with primary antibody (an anti-phosphotyrosine (anti-PY) antibody 4G10 (Upstate Biotechnology Inc.), 1 μ g/ml; anti-pp125^{FAK}, 1 μ g/ml; anti-pp60^{Src}, 1 μ g/ml; anti-paxillin, 1:5,000; or anti-Eyk, 1:5,000. After extensive washing in Tris-buffered saline containing 0.05% Tween-20, blots were incubated with secondary antibody (horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit, 1:5,000 in TBST) (Bio-Rad Laboratories, Richmond, CA) for 1 h at room temperature. Bound antibodies were detected using enhanced chemiluminescence (Amersham, Oakville, Ontario, Canada). Bound antibodies were removed by incubating the blot for 30 min at 50°C in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 100 mM 2-mercaptoethanol. The blots were then reprobed with specific antibodies against pp125^{FAK}, paxillin, pp60^{Src} and c-Eyk. In a few experiments, the proteins were also visualized by silver staining according to the manufacturer's protocol (Bio-Rad Laboratories).

Protein tyrosine kinase assay. Protein tyrosine kinase assays were conducted according to the method described by Maher in reference 11. Briefly, 25- μ g aliquots of detergent soluble protein in a total volume of 50 μ l containing 50 μ M Tris-HCl (pH 7.4), 10 mM MgCl₂, 10 mM MnCl₂, 50 μ M sodium orthovanadate, 50 μ M ATP, 2 μ ci [γ -³²P] ATP (10 mCi/ml, Amersham) and 1 mg/ml poly (Glu/Tyr; 4:1), a synthetic tyrosine kinase substrate (Sigma Chemical Co.), were incubated for 20 min at 30°C. The reactions were stopped by the addition of 15 μ l of boiling 5 \times SDS sample buffer. The phosphorylation of




Figure 1. Vitamin K₁ induces protein tyrosine phosphorylation during early embryogenesis. Eggs were injected with vitamin K₁ on day 10 and brain tissue was obtained 48 h later. (A) Anti-PY immunoblot of detergent soluble proteins from day 12 brain showing vitamin K₁-induced tyrosine phosphorylation. (B) Silver-stained gel showing no change in the level of day 12 brain proteins in the presence of vitamin K₁. (C) As A, except that warfarin was injected together with varying doses of vitamin K₁. Equivalent results were obtained in five individual experiments. The positions of tyrosine phosphorylated proteins exhibiting changes, and $M_r \times 10^{-3}$ are indicated.

poly (Glu/Tyr; 4:1) was monitored after separation of proteins by SDS-PAGE (10%) followed by autoradiography. The blank reaction mixture, containing no peptide substrate or tissue protein, was processed identically, run in parallel lanes, and the counts from these lanes were subtracted from those containing both substrate and tissue protein.

Protein tyrosine phosphatase assay. The assay for protein tyrosine phosphatase activity used phosphotyrosine (Sigma Chemical Co.) as substrate. The reaction mixture (50 μ l) containing 50 μ g of detergent soluble proteins, 25 mM imidazole HCl (pH 7.2), 0.1% β -mercaptoethanol, and 10 mM phosphotyrosine was incubated for 10 min at 30°C. After termination of the reaction by the addition of 50 μ l of 10 mg/ml bovine serum albumin and 150 μ l of 25% TCA, samples were vortexed, incubated for 10 min on ice, and centrifuged at 14,000 g for 5 min. The inorganic phosphate in the supernatant was assayed as described in reference 28. The blank reaction mixture, containing no tissue protein, was processed identically and the values were subtracted from those containing tissue protein. The presence of 200 μ M sodium orthovanadate in the reaction mixtures inhibited > 95% phosphatase activity measured by this assay.

Src kinase assay. pp60^{Src} activity was assayed according to methods supplied by the manufacturer using synthetic peptides derived from p34^{cd2} (Upstate Biotechnology Inc.). Anti-pp60^{Src} immune complexes were incubated for 15 min at 30°C with 50 μ l of kinase reaction buffer containing 50 mM Tris-HCl (pH 7.0), 25 mM MgCl₂, 5 mM MnCl₂, 250 μ M sodium orthovanadate, 100 μ M $[\gamma$ -³²P]ATP, and 300 μ M substrate peptide. The reaction was terminated by the addition of 50% acetic acid, and 25- μ l aliquots of the reaction mixture was spotted onto a phosphocellulose filter paper strip. The strips were washed four times with excess 0.75% phosphoric acid, once with acetone, and then dried. The dried strips suspended in 5 ml of liquid scintillation fluid were counted for radioactivity.

Results

Alterations in levels or metabolism of vitamin K₁ modulate protein tyrosine phosphorylation in embryonic tissues. Although administration of vitamin K₁ had no effect on the overall expression of the proteins in the brain of day 12 embryos (Fig. 1 B), a major increase in tyrosine phosphorylation of proteins of apparent M_r 150–170, 120–130, 105–110, 67–70, and 55–60 kD was observed at vitamin K₁ doses of 0.45 μ g and 4.5 μ g per embryo (Fig. 1 A). The vitamin K₁-dependent modulation of tyrosine phosphorylation is not exclusive to brain—a similar pattern was observed in the liver of these embryos (data not shown). Decreased tyrosine phosphorylation observed with the highest dose of vitamin K₁ (45 μ g) may represent phyloquinone toxicity in the smaller embryo. Warfarin, an inhibitor of K₁ epoxide reductase, reduced tyrosine phosphorylation in a dose-dependent manner at a K₁ dose of 0.45 μ g. The inhibitory effects of warfarin did not occur when the concentration of vitamin K₁ was increased to 4.5 μ g, consistent with the provision of sufficient vitamin K₁ to by pass the metabolic block. At high warfarin doses, tyrosine phosphorylation of many proteins was downregulated to well below their basal level (Fig. 1 C).

Vitamin K₁ upregulates protein tyrosine phosphorylation and protein tyrosine kinase activity in late embryogenesis. As it has been demonstrated previously (10) that tyrosine phosphorylation decreases towards the time of hatch (day 21), we examined the vitamin K₁ effect in older embryos. Consistent with previous reports, control values for tyrosine phosphorylation




Figure 2. Vitamin K₁ upregulates the lower levels of protein tyrosine phosphorylation and tyrosine kinase activity in late embryogenesis. (A) Anti-PY immunoblot of detergent soluble proteins from day 18 brain showing vitamin K₁-induced dose-dependent increase in tyrosine phosphorylation of several proteins. Eggs were injected with vitamin K₁ on day 16 and brain tissue obtained 48 h later was homogenized in RIPA lysis buffer as described in Methods. Proteins (50 μ g) separated by SDS-PAGE (7.5%) were transferred to nitrocellulose and blots probed with an anti-PY antibody. Equivalent results were obtained in five individual experiments. The positions of tyrosine phosphorylated proteins exhibiting changes, and $M_r \times 10^{-3}$ are indicated. (B) Vitamin K₁-induced protein tyrosine kinase activity in day 18 embryonic brain. The protein-tyrosine kinase activity was measured by the phosphorylation of synthetic random amino acid copolymer substrate as described in reference 11. Data are plotted as the specific activity of the tyrosine kinases in pmol/min per mg protein. Results are the average of four determinations (mean \pm SE).




Figure 3. Increased tyrosine phosphorylation of c-Eyk in the brain of vitamin K₁-pretreated day 12 embryos. After injection of vitamin K₁ on day 10, brain tissue obtained on day 12 was homogenized in RIPA lysis buffer and c-Eyk immunoprecipitated as described. Anti-Eyk immunoprecipitates (i.p.) from detergent soluble lysates of brain of day 12 embryos were immunoblotted (i.b.) with anti-PY antibody to monitor the tyrosine phosphorylation of c-Eyk, and reprobed with anti-Eyk antibody for protein expression. Equivalent results were obtained in three individual experiments.

on day 18 were significantly lower than those on day 12 (Figs. 2 A and 1 A); however, following the administration of vitamin K₁, a marked increase in tyrosine phosphorylation of proteins of M_r 150–170, 120–130, 105–110, 67–70, and 55–60 kD was observed at both times. In the older, larger embryos, maximum effect on tyrosine phosphorylation was observed at vitamin K₁ doses 10-fold higher than that observed for the smaller day 12 embryos. The protein tyrosine phosphatase activity in brain of day 12 and day 18 embryos showed no significant change in the presence of vitamin K₁ (data not shown). In contrast, the protein-tyrosine kinase activity, as measured by the phosphorylation of synthetic random amino acid copolymer peptide substrates, increased up to threefold with increasing doses of vitamin K₁ from 0.45 µg to 45 µg (Fig. 2 B).

Tyrosine phosphorylation of c-Eyk is increased by vitamin K₁ supplementation. Western blot analysis using anti-c-Eyk antiserum confirmed the identity of the 105–110 kD band that

exhibited modulation in its phosphotyrosine content in the presence of vitamin K₁ and warfarin (Fig. 1 A, 1 C, 2 A) as c-Eyk. Anti-Eyk immunoprecipitates of day 12 brain of the control and the vitamin K₁ pretreated embryos were then analyzed to establish whether the observed changes are resident in posttranslational tyrosine phosphorylation or due to increased synthesis of protein. Immunoprecipitates were first analyzed with anti-PY immunoblotting, and subsequently with anti-Eyk antiserum. While the c-Eyk immunoprecipitates from both the control and the vitamin K₁ pretreated embryos contained equivalent amounts of c-Eyk protein, a major increase in c-Eyk tyrosine phosphorylation was observed only in the vitamin K₁-treated embryos (Fig. 3).

Focal adhesion kinase (pp125^{FAK}), paxillin, and pp60^{Src} are major components of vitamin K₁-dependent tyrosine phosphorylation cascade during chick embryogenesis. To identify other components of the vitamin K-induced tyrosine phosphorylation cascade, we focused on proteins that exhibited modulation in the presence of vitamin K₁ (Figs. 1 A, 2 A). Reprobe of days 12 and 18 brain blots (Figs. 1 A and 2 A) with anti-pp125^{FAK}, anti-paxillin, and anti-pp60^{Src} antibodies confirmed the identity of the 120–130 kD band as pp125^{FAK}, the 67–70 kD band as paxillin, and the 55–60 kD band as pp60^{Src}. While anti-pp125^{FAK} and anti-paxillin antibodies immunoprecipitated near equal amounts of pp125^{FAK} and paxillin proteins from the brain and liver of both day 18 control and the vitamin K₁ pretreated embryos, only in the vitamin K₁ treated embryos were major increases in tyrosine phosphorylation of these proteins observed (Fig. 4 A, 4 B). Furthermore, anti-Src immune-complexes isolated from embryos pretreated with vitamin K₁ exhibited up to a 2.5-fold increase in the phosphorylation of a synthetic peptide (KVRKIGEGTYGVVKK) derived from amino acids 6–20 of p34^{cdc2} with Tyr-19 replaced by Lys (Fig. 5). The 150–170 kD protein that exhibited a dramatic change in tyrosine phosphorylation in the presence of vitamin K₁ or war-




Figure 4. Identification of pp125^{FAK} and paxillin as tyrosyl proteins modulated by vitamin K₁ in day 18 embryonic brain and liver. pp125^{FAK} and paxillin were immunoprecipitated (i.p.) from detergent soluble lysates of brain (A) and liver (B) of day 18 embryos. Proteins were resolved by SDS-PAGE (7.5%), transferred to nitrocellulose, and analyzed by anti-PY immunoblotting (i.b.) to monitor vitamin K₁-induced changes in tyrosine phosphorylation. The blots were stripped and reprobed with anti-FAK or anti-paxillin antibodies for protein expression. Equivalent results were obtained in three individual experiments.




Figure 5. Anti-Src immune complexes isolated from the brain of day-18-old embryos treated with vitamin K₁ exhibited increased phosphorylation of p34^{cdc2} peptides. pp60^{src} protein was immunoprecipitated from the detergent soluble lysates of day 18 brain as described in Methods. Immune complexes were assayed for phosphorylation of a synthetic peptide (KVRKIGEGTYGVVKK) derived from amino acids 6–20 of pp60^{src} with Tyr-19 replaced by Lys. The results are expressed as mean \pm SD of three independent experiments.

farin (Figs. 1, A and C, 2 A) is not PLC γ 1—its identity remains to be determined.

Discussion

Protein tyrosine phosphorylation plays a pivotal role in the precise regulation of cell division, differentiation, and migration required for normal embryogenesis (29–33). Recent identification of vitamin K-dependent proteins as classical ligands for the Tyro family of RTKs (17–22) together with studies showing the role of vitamin K metabolism and function in two well characterized human birth defects, warfarin embryopathy (34) and vitamin K epoxide reductase deficiency (35), suggest the involvement of a vitamin K-dependent pathway(s) during embryonic development. In the present study we have demonstrated the existence of a vitamin K₁-sensitive tyrosine phosphorylation cascade in the developing chick embryo. That this cascade involves key intracellular proteins, including pp125^{FAK}, paxillin, and pp60^{src}, and responds to alteration in levels or metabolism of vitamin K₁, implies an important role for vitamin K₁-dependent signals in embryogenesis. Whether this vitamin K₁ effect is mediated by the γ -carboxylation of K-dependent proteins or by a mechanism independent of this cofactor activity has not been established.

The overall level of tyrosine phosphorylation is high in chick embryonic tissues during the early stages of development, decreases significantly during late embryogenesis, and is low or undetectable in the same tissues of the adult (10). In these studies, supplementation with vitamin K₁ both at an early stage (day 10) or at a later stage (day 16), significantly increased the tyrosine phosphorylation of several proteins in brain (Figs. 1 A, 2 A) and liver (data not shown). These ty-

rosine phosphorylated proteins, modulated in the presence of vitamin K₁, are similar to those previously shown to exhibit temporal changes in their level of tyrosine phosphorylation during chick embryonic development (10). Based on body weight, these effects were observed with doses of vitamin K₁ at or well below the usual prophylactic dose given to the full term human neonate. The effects of vitamin K₁ on protein-tyrosine phosphorylation were due neither to an effect on the overall expression of proteins (Fig. 1 B), nor to an effect on protein-tyrosine phosphatase activity (data not shown). Rather, vitamin K₁ supplementation caused an increase in protein-tyrosine kinase activity—up to threefold in day 16 brain (Fig. 2 B). Warfarin, an inhibitor of K₁ epoxide reductase that interrupts the recycling of vitamin K₁ from the epoxide to the hydroquinone form, inhibited the effects of low dose vitamin K₁ (0.45 μ g) on tyrosine phosphorylation in the brain of day 12 embryos (Fig. 1 C); no inhibition was observed at higher vitamin K₁ levels sufficient to bypass the metabolic block. To our knowledge, this is the first demonstration of the inhibitory effects of warfarin on tyrosine phosphorylation during embryonic development and provides a possible explanation for the fetal toxicity of this drug (34).

c-Eyk, a 106K chicken counterpart of the Tyro 12 family of RTKs, exhibits a broad spatial and temporal expression during embryonic development (26). The 105–110 K band, which exhibited major alterations in phosphotyrosine content in the presence of vitamin K₁ and warfarin (Figs. 1, A and C, 2 A), was identified as c-Eyk by western blot analysis. Analysis of c-Eyk immunoprecipitates from the detergent soluble lysates of day 12 brain demonstrated that vitamin K₁ induced a major increase in its tyrosine phosphorylation in the absence of any change in the expression of c-Eyk protein (Fig 3). Although these studies suggest the involvement of c-Eyk in this vitamin K₁-induced tyrosine phosphorylation cascade, they do not exclude the possibility that other receptor systems may also mediate the effects of vitamin K₁ during embryonic development.

Protein expression and tyrosine phosphorylation of a cytoplasmic focal adhesion protein-tyrosine kinase (pp125^{FAK}) and its potential substrate paxillin are under developmental control (36, 37). Our studies demonstrate that vitamin K₁ supplementation induces tyrosine phosphorylation of pp125^{FAK} and paxillin in brain and liver of the day 18 embryo without modifying the expression of these proteins (Fig 4 A, B). It is known that autophosphorylation of pp125^{FAK} at tyrosine (Tyr)-397 generates an SH-2 mediated interaction with a member of the Src family (38). This interaction enzymatically activates the Src family kinase which, in turn, phosphorylates Tyr-407, Tyr-576, and Tyr-577 of pp125^{FAK} to fully activate this kinase (39). Consistent with these observations, the 55–60 K band that exhibited increased tyrosine phosphorylation in the presence of K₁ (Figs. 1 A, 2 A) was identified as pp60^{src} by Western blot analysis using anti-pp60^{src} antibody. Furthermore, anti-Src immune complexes isolated from embryos pretreated with vitamin K₁ showed up to a 2.5-fold increase in the phosphorylation of a synthetic peptide (Fig. 5). The concomitant increase in the tyrosine phosphorylation of pp125^{FAK} as well as paxillin, an *in vivo* substrate of both pp125^{FAK} and pp60^{src} (40), is consistent with the propagation of growth regulatory signals in a vitamin K₁-induced cascade (Figs. 4, A and B), and suggests that alterations in the levels of vitamin K₁ during embryogenesis may result in dysregulation of cell-cell or cell-matrix adhesion and other growth regulatory pathways.

Previous work from these laboratories relating to the possible regulatory effects of K_1 has recently been summarized (41). It is of more than passing interest that vitamin K_1 is maintained at low concentration in the human fetus and rises slowly to adult levels after birth in breast-fed babies unsupplemented with vitamin K. In most western countries vitamin K_1 is now administered orally or intramuscularly to prevent hemorrhagic disease due to low levels of the vitamin K-dependent coagulation factors at the time of birth (42). The inhibition of protein-tyrosine phosphorylation by warfarin is consistent with its known toxicity to the human fetus (34), as warfarin crosses the placenta and results in fetal death or skeletal anomalies similar to those described in congenital vitamin K epoxide reductase deficiency (35). The present studies suggest that vitamin K_1 is an important element in embryonic development and may explain, at least in part, the advantage of limiting its concentration in the mammalian and human fetus by a tightly regulated maternal/fetal placental gradient (6). This demonstration of a novel role of vitamin K_1 in the tyrosine phosphorylation cascade involving cytoskeletal proteins argues for the importance of tightly controlled levels of vitamin K_1 in the regulation of embryogenesis.

Acknowledgments

We thank Dr. H. Hanafusa (The Rockefeller University) for the generous gift of the anti-Eyk antibody.

This work was supported by grants from the Heart and Stroke Foundation of Manitoba (S.P. Saxena), the Children's Hospital Research Foundation, Winnipeg (S.P. Saxena), and by the Manitoba Medical Services Foundation (S.P. Saxena and L.G. Israels). S.P. Saxena is a recipient of a Heart and Stroke Foundation of Canada Scholarship.

References

1. Shearer, M.J. 1992. Vitamin K metabolism and nutrition. *Blood Rev.* 6: 92-104.
2. Olson, R.E. 1984. The function and metabolism of vitamin K. *Annu. Rev. Nutr.* 4:281-337.
3. Dowd, P., S.W. Ham, S. Naganathan, and R. Hershtine. 1995. The mechanism of action of vitamin K. *Annu. Rev. Nutr.* 15:419-440.
4. Nelsestuen, G.L. 1976. Role of gamma-carboxyglutamic acid. An unusual transition required for calcium-dependent binding of prothrombin to phospholipids. *J. Biol. Chem.* 251:5648-5656.
5. Furie, B., and B.C. Furie. 1990. Molecular basis of vitamin K-dependent γ -carboxylation. *Blood* 75:1753-1762.
6. Shearer, M.J., S. Rahim, P. Barkhan, and L. Stimmler. 1982. Plasma vitamin K_1 in mothers and their newborn babies. *Lancet* ii:460-463.
7. von Kries, R., F.R. Greer, and J.E. Suttie. 1993. Assessment of vitamin K status of the newborn infants. *J. Pediatric Gastroenterol. Nutr.* 16:231-237.
8. Pasquale, E.B., and S.J. Singer. 1989. Identification of a developmentally regulated protein-tyrosine kinase by using anti-phosphotyrosine antibodies to screen a cDNA expression library. *Proc. Natl. Acad. Sci. USA* 86:5449-5453.
9. Adamson, E.D. 1987. Oncogenes in development. *Development (Camb.)* 99:449-471.
10. Maher, P.A., and E.B. Pasquale. 1988. Tyrosine phosphorylated proteins in different tissues during chick embryo development. *J. Cell Biol.* 106: 1747-1755.
11. Maher, P.A. 1991. Tissue-dependent regulation of protein tyrosine kinase activity during embryonic development. *J. Cell Biol.* 112:955-963.
12. Lai, C., and G. Lemke. 1991. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. *Neuron* 6: 691-704.
13. Edelman, G.M., and K.L. Crossin. 1991. Cell adhesion molecules: Implications for a molecular histology. *Annu. Rev. Biochem.* 60:155-190.
14. Krueger, N.X., and H. Saito. 1992. A human transmembrane protein-tyrosine phosphatase, PTP ζ , is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrase. *Proc. Natl. Acad. Sci. USA* 89: 7417-7421.
15. Dahlback, B. 1991. Protein S and C4B-binding protein: components involved in the regulation of the protein C anticoagulant system. *Thromb. Haemostasis* 66:49-61.
16. Manfioletti, G., C. Brancolini, G. Avanzi, and C. Schneider. 1993. The protein encoded by a growth arrest-specific gene (*gas6*) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. *Mol. Cell. Biol.* 13:4976-4985.
17. Varum, B.C., C. Young, G. Elliott, A. Garcia, T.D. Bartley, Y.W. Fridell, R.W. Hunt, G. Trail, C. Clogston, R.J. Toso et al. 1995. *Axl* receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene6. *Nature (Lond.)* 373:623-626.
18. Stitt, T.N., G. Conn, M. Gore, C. Lai, J. Bruno, C. Radziejewski, K. Mattsson, J. Fisher, D.R. Gies, P.F. Jones et al. 1995. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/*Axl* family of receptor tyrosine kinases. *Cell* 80:661-670.
19. Godowski, P.J., M.R. Mark, J. Chen, M.D. Sadick, H. Raab, and R.G. Hammonds. 1995. Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinases Rse/Tyro3. *Cell* 82:355-358.
20. Mark, M.R., J. Chen, R.G. Hammonds, M. Sadick, and P.J. Godowski. 1996. Characterization of Gas6, a member of the superfamily of G Domain-containing proteins, as a ligand for Rse and *Axl*. *J. Biol. Chem.* 271:9785-9789.
21. Nakano, T., J. Kishino, and H. Arita. 1996. Characterization of a high-affinity and specific binding site for Gas6. *FEBS Lett.* 387:75-77.
22. Ohashi, K., K. Nagata, J. Tushima, T. Nakano, H. Arita, H. Tsuda, K. Suzuki, and K. Mizuno. 1995. Stimulation of Sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. *J. Biol. Chem.* 270:22681-22684.
23. O'Bryan, J.P., R.A. Frye, P.C. Cogswell, A. Neubauer, B. Kitch, C. Prokop, R. Espinosa, M.M. Le Beau, H.S. Earp, and E.T. Liu. 1991. *axl*, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. *Mol. Cell. Biol.* 11:5016-5031.
24. McCloskey, P., J. Pierce, R.A. Koski, B. Varum, and E.T. Liu. 1994. Activation of the *Axl* receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. *Cell Growth Differ.* 5:1105-1117.
25. Gasic, G.P., C.P. Arenas, T.B. Gasic, and G.J. Gasic. 1992. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. *Proc. Natl. Acad. Sci. USA* 89:2317-2320.
26. Jia, R., and H. Hanafusa. 1994. The proto-oncogene of *v-ryk* (*v-ryk*) is a novel receptor-type protein kinase with extracellular Ig/FN-III domains. *J. Biol. Chem.* 269:1839-1844.
27. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)* 227:680-685.
28. Chen, P.S., T.Y. Toribara, and H. Warner. 1956. Microdetermination of phosphorus. *Anal. Chem.* 28:1756-1758.
29. Sprenger, F., L.M. Stevens, and C.N. Volhard. 1989. The *Drosophila* gene *torso* encodes a putative receptor tyrosine kinase. *Nature (Lond.)* 338: 478-483.
30. Basler, K., and E. Hafen. 1988. Control of photoreceptor cell fate by the *sevenless* protein requires a functional tyrosine kinase domain. *Cell* 54:299-311.
31. Aroian, R.V., M. Koga, J.E. Mendel, Y. Ohshima, and P.W. Sternberg. 1990. The *let-23* gene necessary for *Caenorhabditis elegans* vulval induction encodes a tyrosine kinase of the EGF receptor subfamily. *Nature (Lond.)* 348: 693-699.
32. Raff, M.C., L.E. Lillien, W.D. Richardson, J.F. Burne, and M.D. Nobel. 1988. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. *Nature (Lond.)* 333:562-565.
33. Barres, B.A., I.K. Hart, H.S. Coles, J.F. Burne, J.T. Voyvodic, W.D. Richardson, and M.C. Raff. 1992. Cell death and control of cell survival in the oligodendrocyte lineage. *Cell* 70:31-36.
34. Hall, J.G., Pauli, R.M. & Wilson, K.M. 1980. Maternal and fetal sequelae of anticoagulation during pregnancy. *Am. J. Med.* 68:122-140.
35. Pauli, R.M., J.B. Lian, D.F. Mosher, and J.W. Suttie. 1987. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivative. *Am. J. Hum. Genet.* 41:566-583.
36. Turner, C.E., M.D. Schaller, and J.T. Parsons. 1993. Tyrosine phosphorylation of the focal adhesion kinase pp125^{FAK} during development: relation to paxillin. *J. Cell Sci.* 105:637-645.
37. Turner, C.E. 1991. Paxillin is a major phosphotyrosine-containing protein during embryonic development. *J. Cell Biol.* 115:201-207.
38. Schaller, M.D., J.D. Hildebrand, J.D. Shannon, J.W. Fox, R.R. Vines, and J.T. Parsons. 1994. Autophosphorylation of the focal adhesion kinase, pp125^{FAK}, directs SH2-dependent binding of pp60^{src}. *Mol. Cell. Biol.* 14:1680-1688.
39. Calalb, M.B., T.R. Polte, and S.K. Hanks. 1995. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family of kinases. *Mol. Cell. Biol.* 14:954-963.
40. Turner, C.E. 1994. Paxillin: a cytoskeletal target for tyrosine kinases. *Bioessays* 16:47-52.
41. Israels, L.G., and E.D. Israels. 1995. Observations on vitamin K deficiency in the fetus and newborn. Has nature made a mistake? *Semin. Thromb. Hemostasis* 21:364-370.
42. von Kries, R., M.J. Shearer, and U. Gobel. 1988. Vitamin K in infancy. *Eur. J. Pediatr.* 147:106-112.